Refining psychiatric phenotypes for response to treatment: Contribution of LPHN3 in ADHD

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 159 B, Issue 7, 2012, Pages 776-785

  Labbe, Aurelie ^a,b   Liu, Andy ^a   Atherton, Juli ^c   Gizenko, Natalie ^a,b   Fortier, Marie Ève ^a,b   Sengupta, Sarojini M ^a,b   Ridha, Joober ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Actiwatch; ADHD; Latent class; LPHN3; Phenotype definition

Indexed keywords

BIOLOGICAL MARKER; LATROPHILIN 3; METHYLPHENIDATE; PLACEBO; UNCLASSIFIED DRUG;

ACTIWATCH; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; MOTOR ACTIVITY; PHENOTYPE; PLACEBO EFFECT; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD; TREATMENT RESPONSE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CROSS-OVER STUDIES; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; METHYLPHENIDATE; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE;

EID: 84866314265     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32083     Document Type: Article

References (31)

1. Aman CJ, Roberts RJ, Pennington BF. 1998. A neuropsychological examination of the underlying deficit in attention deficit hyperactivity disorder: Frontal lobe versus right parietal lobe theories. Dev Psychol 34(5): 956-969.
2. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders, fourth edition. Washington DC: American Psychiatric Association.
3. Arcos-Burgos M, Castellanos FX, Pineda D, Lopera F, Palacio JD, Palacio LG, Rapoport JL, Berg K, Bailey-Wilson JE, Muenke M. 2004. Attention-deficit/hyperactivity disorder in a population isolate: Linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. Am J Hum Genet 75(6): 998-1014.
4. Arcos-Burgos M, Jain M, Acosta MT, Shively S, Stanescu H, Wallis D, Domene S, Velez JI, Karkera JD, Balog J, et al. 2010. A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication. Mol Psychiatry 15(11): 1053-1066.
5. Arnsten AFT. 2009. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: An important role for prefrontal cortex dysfunction. Cns Drugs 23: 33-41.
6. Breen MJ. 1989. Cognitive and behavioral-differences in ADHD boys and girls. J Child Psychol Psychiatry 30(5): 711-716.
7. Choudhry Z, Sengupta SM, Grizenko N, Fortier M, Thakur GA, Bellingham J, Robinson S, Ter Stepanian M, Polotskaia A, Joober R. 2012. LPHN3 and attention-deficit/hyperactivity disorder: Interaction with maternal stress during pregnancy. J Child Psychol Psychiatry 53(8): 892-902.
8. Conners CK, Barkley RA. 1985. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 21: 809-843.
9. Conners C, Sitarenios G, Parker JD, Epstein JN. 1998. The revised Conners Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26: 257-268.
10. Davletov BA, Meunier FA, Ashton AC, Matsushita H, Hirst WD, Lelianova VG, Wilkin GP, Dolly JO, Ushkaryov YA. 1998. Vesicle exocytosis stimulated by alpha-latrotoxin is mediated by latrophilin and requires both external and stored Ca2+. EMBO J 17(14): 3909-3920.
11. Ehrich M, Bocker S, van den Boom D. 2005. Multiplex discovery of sequence polymorphisms using base-specific cleavage and MALDI-TOF MS. Nucleic Acid Res 3(4): e38.
12. Fanous AH, Neale MC, Webb BT, Straub RE, O'Neill FA, Walsh D, Riley BP, Kendler KS. 2008. Novel linkage to chromosome 20p using latent classes of psychotic illness in 270 Irish high-density families. Biol Psychiatry 64(2): 121-127.
13. Faraone SV, Wigal SB, Hodgkins P. 2007. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD. J Atten Disord 11(1): 74-82.
14. Fischer M, Newby RF. 1998. Use of the restricted academic task in ADHD dose-response relationships. J Learn Disabil 31(6): 608-612.
15. Holliday E, McLean DE, Dale MA, Nyholt R, Mowry BJ. 2009. Susceptibility locus on chromosome 1q23-25 for a schizophrenia subtype resembling deficit schizophrenia identified by latent class analysis. Arch Gen Psychiatry 66(10): 1058-1067.
16. Jain M, Vélez JI, Acosta MT, Palacio LG, Balog J, Roessler E, Pineda D, Londoño AC, Palacio JD, Arbelaez A, et al. 2012. A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD. Mol Psychiatry 17(7): 741-747.
17. Konrad K, Eickhoff SB. 2010. Is the ADHD brain wired differently? A review on structural and functional connectivity in attention deficit hyperactivity disorder. Hum Brain Mapp 31(6): 904-916.
18. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. 2000. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285(2): 107-110.
19. Kreienkamp HJ, Zitzer H, Gundelfinger ED, Richter D, Bockers TM. 2000. The calcium-independent receptor for alpha-latrotoxin from human and rodent brains interacts with members of the ProSAP/SSTRIP/Shank family of multidomain proteins. J Biol Chem 275(42): 32387-32390.
20. Makris N, Biederman J, Monuteaux MC, Seidman LJ. 2009. Towards conceptualizing a neural systems-based anatomy of attention-deficit/hyperactivity disorder. Dev Neurosci 31(1-2): 36-49.
21. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. 2007. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 164(6): 942-948.
22. Rahman MA, Ashton AC, Meunier FA, Davletov BA, Dolly JO, Ushkaryov YA. 1999. Norepinephrine exocytosis stimulated by alpha-latrotoxin requires both external and stored Ca2+ and is mediated by latrophilin, G proteins and phospholipase C. Philos Trans R Soc Lond B Biol Sci 354(1381): 379-386.
23. Ribasés M, Ramos-Quiroga JA, Sánchez-Mora C, Bosch R, Richarte V, Palomar G, Gastaminza X, Bielsa A, Arcos-Burgos M, Muenke M, et al. 2011. Contribution of LPHN3 to the genetic susceptibility to ADHD in adulthood: A replication study. Genes Brain Behav 10(2): 149-157.
24. Schaffer D, Fisher P, Lucas C, Dulcan M, Schwab-Stone M. 2000. NIMH Diagnostic In- terview Schedule for Children Version IV (NIMH DISC-IV): Description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 39: 28-38.
25. Shastry BS. 2004. Molecular genetics of attention-deficit hyperactivity disorder (ADHD): An update. Neurochem Int 44(7): 469-474.
26. Shaw P, Rabin C. 2009. New insights into attention-deficit/hyperactivity disorder using structural neuroimaging. Curr Psychiatry Rep 11(5): 393-398.
27. Silva JP, Suckling J, Ushkaryov Y. 2009. Penelope's web: Using alpha-latrotoxin to untangle the mysteries of exocytosis. J Neurochem 111(2): 275-290.
28. Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4): 978-989.
29. Sun HB, Ruan YW, Xu ZC, Yokota H. 2002. Involvement of the calcium-independent receptor for alpha-latrotoxin in brain ischemia. Mol Brain Res 104(2): 246-249.
30. Volkow ND, Ding U, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey SL, Ashby C, Lieberman J, Hitzemann R, Wolf AP. 1995. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiatry 52: 456-463.
31. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hit-zemann R, Pappas N. 1998. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphe- nidate. Am J Psychiatry 155: 1325-1331.